Profile data is unavailable for this security.
About the company
Cara Therapeutics, Inc. is a development-stage biopharmaceutical company. The Company is focused on treatment paradigm to improve the lives of patients suffering from chronic pruritus. It is developing an oral formulation of difelikefalin, a selective, predominantly peripherally acting, non-scheduled Kappa opioid receptor agonist, for the treatment of chronic neuropathic pruritus associated with Notalgia Paresthetica (NP), a common, underdiagnosed neuropathy affecting the upper back. It is conducting Phase II/III Clinical Program in NP. The program is comprised of two studies - KOURAGE 1 and KOURAGE 2, which are double-blind, placebo-controlled, eight-week studies with patients allowed to roll-over into open-label 52-week extensions. It has developed an IV formulation of difelikefalin, for the treatment of moderate-to-severe pruritus associated with advanced chronic kidney disease in adults undergoing hemodialysis. The IV formulation is out-licensed worldwide.
- Revenue in USD (TTM)11.00m
- Net income in USD-111.08m
- Incorporated2004
- Employees55.00
- LocationCara Therapeutics Inc400 Atlantic Street, Suite 500STAMFORD 06901United StatesUSA
- Phone+1 (203) 406-3700
- Fax+1 (203) 567-1510
- Websitehttps://www.caratherapeutics.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Lotus Pharmaceuticals Inc | 70.79m | 1.72m | 7.81m | 233.00 | 0.0524 | 0.0008 | 2.03 | 0.1104 | 0.0553 | 0.0553 | 2.56 | 3.58 | 0.6321 | 37.27 | 17.85 | 303,836.90 | 1.55 | 22.84 | 1.71 | 26.40 | 35.10 | 41.62 | 2.45 | 19.93 | 0.4428 | 30.80 | 0.0516 | 0.00 | 28.71 | 31.70 | -12.22 | 51.11 | 70.48 | -- |
CV Sciences Inc | 15.85m | -2.53m | 8.50m | 42.00 | -- | 3.39 | -- | 0.5366 | -0.0157 | -0.0157 | 0.098 | 0.0139 | 1.69 | 1.55 | 25.35 | 377,285.70 | -26.94 | -43.42 | -73.44 | -77.75 | 46.06 | 51.81 | -15.95 | -45.68 | 0.2530 | -- | 0.0114 | -- | -1.24 | -19.80 | 133.96 | -20.87 | -- | -- |
Aptorum Group Ltd | 431.38k | -2.82m | 9.68m | 3.00 | -- | 0.3691 | -- | 22.45 | -0.9126 | -0.9126 | 0.0954 | 4.80 | 0.0208 | 30.36 | 3.88 | 143,793.30 | -20.92 | -40.45 | -19.62 | -42.36 | 2.45 | -4.04 | -1,006.30 | -1,233.68 | 1.18 | -- | 0.1694 | -- | -66.71 | 2.38 | 71.18 | -- | -78.15 | -- |
Bright Green Corp | 0.00 | -9.92m | 9.79m | 5.00 | -- | 0.993 | -- | -- | -0.0538 | -0.0538 | 0.00 | 0.0519 | 0.00 | -- | -- | 0.00 | -47.48 | -- | -72.55 | -- | -- | -- | -- | -- | -- | -- | 0.0494 | -- | -- | -- | 52.54 | -- | -- | -- |
Healthy Extracts Inc | 2.88m | -1.37m | 10.72m | -- | -- | 26.79 | -- | 3.72 | -0.4725 | -0.4725 | 0.9845 | 0.1336 | 1.12 | 0.6654 | 28.03 | -- | -53.40 | -53.78 | -168.81 | -146.65 | 67.83 | 45.68 | -47.73 | -87.53 | 0.2059 | -0.9153 | 0.7131 | -- | 10.41 | 105.93 | -151.54 | -- | -- | -- |
NDT Pharmaceuticals Inc | -100.00bn | -100.00bn | 11.84m | 1.00 | -- | 0.0661 | -- | -- | -- | -- | -- | 1.12 | -- | -- | -- | -- | -- | -164.47 | -- | -452.47 | -- | -- | -- | -6,891.36 | -- | -- | 0.00 | -- | -100.00 | -- | 87.56 | -- | -- | -- |
Talphera Inc | 398.00k | -13.70m | 13.42m | 15.00 | -- | 1.05 | -- | 33.73 | -0.6353 | -0.6323 | 0.0185 | 0.7491 | 0.0187 | -- | -- | 26,533.33 | -64.37 | -22.60 | -78.11 | -28.55 | -- | -- | -3,443.22 | -714.87 | -- | -- | 0.00 | -- | -- | -21.26 | -119.16 | -- | -34.33 | -- |
Aytu Biopharma Inc | 81.00m | -15.84m | 14.39m | 99.00 | -- | 0.5043 | -- | 0.1776 | -2.86 | -2.86 | 14.63 | 4.64 | 0.6364 | 2.15 | 3.08 | 818,202.00 | -12.45 | -27.76 | -25.70 | -46.03 | 67.39 | 58.88 | -19.56 | -56.45 | 0.7916 | -0.0594 | 0.3531 | -- | -24.58 | 61.73 | 7.08 | -- | -- | -- |
Cara Therapeutics Inc | 11.00m | -111.08m | 14.60m | 55.00 | -- | 1.26 | -- | 1.33 | -2.04 | -2.04 | 0.2017 | 0.2115 | 0.1063 | 1.10 | 2.10 | 199,927.30 | -107.38 | -35.76 | -132.61 | -40.82 | 74.66 | -- | -1,010.20 | -162.10 | 4.48 | -- | 0.00 | -- | -49.92 | 9.26 | -38.65 | -- | 100.66 | -- |
Nexgel Inc | 5.01m | -3.39m | 16.92m | 19.00 | -- | 3.79 | -- | 3.38 | -0.5722 | -0.5722 | 0.8464 | 0.6589 | 0.4942 | 3.03 | 6.44 | 263,631.60 | -35.74 | -44.61 | -48.15 | -56.19 | 23.74 | 5.02 | -72.33 | -180.98 | 0.8135 | -- | 0.1992 | -- | 99.66 | 13.06 | 33.48 | -- | -- | -- |
Cumberland Pharmaceuticals, Inc. | 37.79m | -10.38m | 17.76m | 91.00 | -- | 0.6735 | -- | 0.47 | -0.7328 | -0.7328 | 2.67 | 1.87 | 0.4501 | 0.8643 | 3.17 | 415,225.80 | -12.35 | -7.03 | -17.75 | -9.52 | 82.58 | 79.95 | -27.45 | -17.64 | 1.26 | -38.85 | 0.382 | -- | -5.85 | 6.15 | -12.73 | -- | -36.17 | -- |
TherapeuticsMD Inc | 996.00k | -4.83m | 19.14m | 1.00 | -- | 0.6918 | -- | 19.22 | -0.4348 | -0.5538 | 0.0889 | 2.40 | 0.0212 | -- | 0.5048 | 996,000.00 | -10.31 | -53.35 | -13.13 | -111.61 | 45.08 | 86.67 | -485.34 | -236.57 | -- | -- | 0.00 | -- | -98.14 | -39.53 | -816.85 | -- | -- | -- |
Tonix Pharmaceuticals Holding Corp | 12.46m | -149.01m | 20.14m | 103.00 | -- | 0.0336 | -- | 1.62 | -110.99 | -110.99 | 6.16 | 4.28 | 0.1083 | 0.8436 | -- | 120,951.50 | -129.55 | -59.46 | -157.22 | -65.92 | 21.59 | -- | -1,196.12 | -5,126.73 | 0.7181 | -- | 0.1678 | -- | -- | -- | 0.1874 | -- | 320.57 | -- |
China Health Industries Holdings, Inc. | 95.95k | -1.36m | 21.30m | 32.00 | -- | -- | -- | 221.99 | -0.0208 | -0.0208 | 0.0015 | -0.0366 | 0.0037 | 0.5035 | 20.57 | 2,998.44 | -5.18 | 3.04 | -6.89 | 3.66 | -5.34 | 69.55 | -1,419.49 | 28.61 | 0.0377 | -- | 1.76 | -- | 41,225.93 | -55.72 | -15.49 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
BlackRock Fund Advisorsas of 31 Mar 2024 | 3.06m | 5.60% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 2.44m | 4.47% |
Disciplined Growth Investors, Inc.as of 31 Mar 2024 | 1.82m | 3.32% |
Chescapmanager LLCas of 31 Mar 2024 | 1.70m | 3.11% |
Farallon Capital Management LLCas of 31 Mar 2024 | 1.56m | 2.85% |
Renaissance Technologies LLCas of 30 Jun 2024 | 1.07m | 1.95% |
SSgA Funds Management, Inc.as of 31 Mar 2024 | 1.00m | 1.83% |
Stifel Nicolaus & Co., Inc. (Investment Management)as of 31 Mar 2024 | 741.37k | 1.36% |
Millennium Management LLCas of 31 Mar 2024 | 661.83k | 1.21% |
Two Sigma Advisers LPas of 31 Mar 2024 | 659.90k | 1.21% |